Pentostatin, cyclophosphamide and rituximab for previously untreated advanced stage, low-grade B-cell lymphomas

Felipe Samaniego*, Fredrick Hagemeister, Jorge E. Romaguera, Michelle A. Fanale, Barbara Pro, Peter Mclaughlin, M. Alma Rodriguez, Sattva S. Neelapu, Luis Fayad, Anas Younes, Lei Feng, Zuzana Berkova, Tamer Khashab, Lalit Sehgal, Francisco Vega-Vasquez, Larry W. Kwak

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

5 Scopus citations


Summary: We conducted a prospective phase II trial of pentostatin, cyclophosphamide and rituximab as initial therapy for patients with previously untreated advanced stage low-grade or indolent B-cell lymphomas (iNHLs). Of 83 evaluable patients, 91·6% attained an overall response and 86·8% a complete or unconfirmed complete response. The 3-year progression-free survival (PFS) and overall survival rates were 73% and 93%, respectively. The 3-year PFS rate was significantly different for different diagnoses (P = 0·01): 83% [95% confidence interval (CI): 0·72, 0·96] for follicular lymphomas, 73% (95% CI: 0·54, 1·0) for marginal zone lymphomas and 61% (95% CI: 0·46, 0·81) for small lymphocytic lymphomas. The most common adverse events were haematological. Of 509 cycles of chemotherapy administered, grade 3 or 4 neutropenia was reported in 68 cycles (13% of cycles administered) and most frequently occurred during cycles 4-6. This is the first report demonstrating the effectiveness of pentostatin, cyclophosphamide and rituximab in patients with previously untreated iNHLs, including those over 60 years of age.

Original languageEnglish (US)
Pages (from-to)814-823
Number of pages10
JournalBritish Journal of Haematology
Issue number6
StatePublished - Jun 1 2015


  • Cyclophosphamide
  • Deoxycoformycin
  • Follicular lymphoma
  • Marginal zone lymphoma
  • Small lymphocytic lymphoma

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Pentostatin, cyclophosphamide and rituximab for previously untreated advanced stage, low-grade B-cell lymphomas'. Together they form a unique fingerprint.

Cite this